Annual report for the Association for Accessible Medicines recapping 2014. View press release to learn more about the successful rebrand.
Recently, an FDA Advisory Committee unanimously recommended that the Agency approve what will be the first biosimilar medicine in the United States. This is an historic development for millions of patients awaiting access to safe, affordable versions of biologics, and an appropriate bookend to our 2014 Annual Meeting when we kicked off a year-long celebration of the 30th anniversary of the landmark Hatch-Waxman Act.
Ralph G. NeasPresident & CEO, Generic Pharmaceutical Association
2014 was the year we celebrated three decades of phenomenal achievements made possible by the landmark Hatch-Waxman Act, the extraordinary legislation that since 1984 has provided millions of Americans access to safe, effective and affordable prescription drugs. To sustain this success, GPhA is dedicated to promoting and protecting the strategic interests of our member companies across multiple fronts.
Our work is challenging, but we have become a proactive and strong advocate for our member companies and for millions of Americans who rely on the safe, effective and affordable generic medicines we produce. We have done this by “speaking with one voice” and engaging across all levels of public policy.
Craig WheelerChairman of the Board, Generic Pharmaceutical Association